Company Overview
Company Type: Private Company
Website: www.novoheart.com
Number of Employees: 15
Year Founded: -
Total Amount Raised (CAD mm)†: 0.33
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.4
Market Capitalization
100.0
EBITDA
(8.9)
EBIT
(9.4)
Cash & ST Invst.
13.4
P/Diluted EPS Before Extra
NM
Net Income
(9.0)
Total Debt
6.3
Price/Tang BV
7.2x
Capital Expenditure
(1.2)
Total Assets
30.7
Total Debt/EBITDA
NM
U.S. Number of Employees 2023
-
U.S. Number of Employees 2022
-
U.S. Last Year Employee Growth %
-
Currency in CAD in mm, LTM as of Jun-30-2020 TEV and Market Cap are calculated using a close price as of Nov-20-2020

Key Professionals
Name
Title
Li, Ronald Adolphus
Scientific Co-Founder, CEO & Director
Costa, Kevin 
Chief Scientific Officer & Scientific Co-Founder
Khine, Michelle 
Scientific Co-Founder & Member of Scientific Advisory Board
Chan, Camie 
Interim CFO, COO, Corporate Secretary & Director

Key Board Members
Name
Title
Ma, Kam-Sing 
Independent Chairman of the Board
Li, Ronald Adolphus
Scientific Co-Founder, CEO & Director
Ying, Ngan Ng Yu 
Deputy Chair of the Board
Khine, Michelle 
Scientific Co-Founder & Member of Scientific Advisory Board
Chan, Camie 
Interim CFO, COO, Corporate Secretary & Director
Chang, Tin Duk 
Independent Director
Topham, James Walter
Independent Director
Chiu, Tong 
Independent Director
Ngan, Chi Wing 
Director
Tomaselli, Gordon 
Member of Scientific Advisory Board
Tung, Leslie 
Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
595 Burrard Street Suite 2600 | Vancouver, BC | V7X 1L3 | Canada
Phone: 604-398-3170   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Novomed Limited
Sep-15-2020
Minority
12.60 %
-
Hong Kong Science and Technology Parks, Investment Arm
Feb-28-2017
Unknown
-
Venture


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Xellera Therapeutics Limited
Xellera Therapeutics Limited develops cell- and gene-based therapies. The company was founded in 2018 and is headquartered in Hung Hom, Hong Kong. As of June 28, 2019, Xellera Therapeutics Limited operates as a subsidiary of Novoheart Holdings Inc.

Asia / Pacific
Biotechnology
-
-
-
Woodrose Ventures Corporation
As of September 27, 2017, Woodrose Ventures Corporation was acquired by Novoheart Holdings Ltd. in a reverse merger transaction. Woodrose Ventures Corporation primarily engages in the oil and gas business in Canada. It has a residual royalty interest in an oil and gas property in Alberta. The company was formerly known as Woodrose Corporation and changed its name to Woodrose Ventures Corporation in November 2016. Woodrose Ventures Corporation was founded in 1985 and is headquartered in Vancouver, Canada.

United States and Canada
Oil and Gas Exploration and Production
0.00
0.00
0.00
Novoheart Limited

Asia / Pacific
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-15-2020
Nov-18-2020
Merger/Acquisition
Target
Novoheart Holdings Inc.
Novomed Limited

10.27
May-28-2019
Jun-28-2019
Merger/Acquisition
Buyer
Xellera Therapeutics Limited
Novoheart Holdings Inc.
Ruby Fame Limited,Marine Bridge International Limited
24.15
Apr-13-2018
-
Shelf Registration
Target
Novoheart Holdings Inc.


47.62
Mar-13-2017
Sep-27-2017
Merger/Acquisition
Buyer
Woodrose Ventures Corporation
Novoheart Holdings Inc.

-
Feb-28-2017
Feb-28-2017
Private Placement
Target
Novoheart Holdings Inc.
Hong Kong Science and Technology Parks, Investment Arm Buyer Funds:Corporate Venture Fund

0.25
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Nov-23-2020
Index Constituent Drops
Novoheart Holdings Inc.(TSXV:NVH) dropped from S&P/TSX Venture Composite Index
Nov-20-2020
Delistings
Novoheart Holdings to Be Deleted from Other OTC
Nov-18-2020
Delistings
Novoheart Holdings Shares Expect to Delist from TSXV on or About November 20, 2020
Nov-18-2020
M&A Transaction Closings
Novomed Limited completed the acquisition of 12.6% stake in Novoheart Holdings Inc. (TSXV:NVH).
Nov-11-2020
Delistings
Novoheart Holdings Inc. to Delist Shares from TSXV

M&A Advisors
Blake, Cassels & Graydon LLP, Evans & Evans, Inc., Farris LLP, KPMG Corporate Finance LLC, McMillan LLP


Advisors
Most Recent Auditor
BDO LLP, KPMG Limited
M&A Advisors
Blake, Cassels & Graydon LLP, Evans & Evans, Inc., Farris LLP, KPMG Corporate Finance LLC, McMillan LLP


Most Recent Auditor
BDO LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Nov 25, 2020 05:00 PM
Novoheart Holdings Inc.
Rating Update for Novoheart Holdings Inc
EPS Estimates*
3
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Nov 09, 2020 07:05 AM
Novoheart Holdings Inc.
Rating Update for Novoheart Holdings Inc
EPS Estimates*
3
Wright Investors' Service Inc.

Oct 31, 2020 01:20 AM
Novoheart Holdings Inc.
Flow of Funds Report for Novoheart Holdings Inc - prepared by Wright Investors Service
Notes
75
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Oct 05, 2020 06:00 PM
Novoheart Holdings Inc.
Rating Update for Novoheart Holdings Inc
EPS Estimates*
3
Wright Investors' Service Inc.

Sep 09, 2020 02:26 AM
Novoheart Holdings Inc.
Wright Investors Service Comprehensive Report for Novoheart Holdings Inc
Notes
68
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Aug 24, 2020 06:00 PM
Novoheart Holdings Inc.
Rating Update for Novoheart Holdings Inc
EPS Estimates*
3
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Aug 07, 2020 06:47 AM
Novoheart Holdings Inc.
Rating Update for Novoheart Holdings Inc
EPS Estimates*
3
SADIF-Investment Analytics S.A.

Apr 08, 2020 07:28 AM
Novoheart Holdings Inc.
Rating Update for Novoheart Holdings Inc
EPS Estimates*
3
SADIF-Investment Analytics S.A.

Jan 01, 2020 05:00 PM
Novoheart Holdings Inc.
Rating Update for Novoheart Holdings Inc
EPS Estimates*
3
SADIF-Investment Analytics S.A.

Nov 19, 2019 05:00 PM
Novoheart Holdings Inc.
Will Novoheart Holdings Inc Build Long-Term Returns?
Ratings Change*
12



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
New Bioera Holdings Limited
0
(37,200,000)
Marine Bridge International Limited
0
(16,740,000)
Costa B.S., Ph.D., Kevin 
0
(780,000)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Human Ventricular Cardiac Organoid Chamber (Future), Human Ventricular Cardiac Tissue Strips (Future), MyHeart


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Nov-27-2020
Novoheart Holdings Inc.
SEDAR
Material Change Report
123 KB
Nov-27-2020
Novoheart Holdings Inc.
SEDAR
Change in Corporate Structure
85 KB
Nov-18-2020
Novoheart Holdings Inc.
SEDAR
Securities Acquisition Filings (Early Warning)
181 KB
Nov-18-2020
Novoheart Holdings Inc.
SEDAR
News Releases
31 KB
Nov-16-2020
Novoheart Holdings Inc.
SEDAR
News Releases
20 KB
Nov-10-2020
Novoheart Holdings Inc.
SEDAR
News Releases
30 KB
Oct-20-2020
Novoheart Holdings Inc.
SEDAR
Management Proxy Materials
135 KB
Oct-19-2020
Novoheart Holdings Inc.
SEDAR
Management Proxy Materials
53 KB
Oct-19-2020
Novoheart Holdings Inc.
SEDAR
Management Proxy Materials
447 KB
Oct-19-2020
Novoheart Holdings Inc.
SEDAR
Management Proxy Materials
2 MB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Ying J.P., Ngan Ng Yu  (Deputy Chair of the Board)
Dec-13-2019
New Common Shares
79,000
43,572
Open Market Acquisition
New
Exchange Announcement
Ying J.P., Ngan Ng Yu  (Deputy Chair of the Board)
Dec-10-2019 - Dec-12-2019
New Common Shares
143,000
71,813
Open Market Acquisition
New
Exchange Announcement
-
Dec-10-2019
New Common Shares
75,000
36,604
Open Market Acquisition
-
Exchange Announcement
-
Dec-10-2019
New Common Shares
5,000
2,388
Open Market Acquisition
-
Exchange Announcement
-
Dec-12-2019
New Common Shares
63,000
32,821
Open Market Acquisition
-
Exchange Announcement
Ying J.P., Ngan Ng Yu  (Deputy Chair of the Board)
Dec-09-2019
New Common Shares
60,000
29,286
Open Market Acquisition
New
Exchange Announcement
Ying J.P., Ngan Ng Yu  (Deputy Chair of the Board)
Dec-06-2019
New Common Shares
72,500
33,268
Open Market Acquisition
1.10
Exchange Announcement
-
Dec-06-2019
New Common Shares
51,000
23,246
Open Market Acquisition
-
Exchange Announcement
-
Dec-06-2019
New Common Shares
21,500
10,022
Open Market Acquisition
-
Exchange Announcement
Fermini Ph.D., Bernard  (Former Chief Research & Development Officer)
Dec-06-2019
New Common Shares
80,000
0
Derivative Exercise and Retained Stock
New
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Ma, Kam-Sing 
Independent Chairman of the Board
604-398-3170
-

Li, Ronald Adolphus
Scientific Co-Founder, CEO & Director
(604) 398-3170
-

Ying, Ngan Ng Yu 
Deputy Chair of the Board
604-398-3170
-

Khine, Michelle 
Scientific Co-Founder & Member of Scientific Advisory Board
604-398-3170
-

Chan, Camie 
Interim CFO, COO, Corporate Secretary & Director
+1 604-398-3170
(604) 375-5578

Chang, Tin Duk 
Independent Director
604-398-3170
-

Topham, James Walter
Independent Director
604-398-3170
-

Chiu, Tong 
Independent Director
604-398-3170
-
ricky@cynosurepe.com
Ngan, Chi Wing 
Director
604-398-3170
-

Tomaselli, Gordon 
Member of Scientific Advisory Board
604-398-3170
-
-
Tung, Leslie 
Member of Scientific Advisory Board
604-398-3170
-
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Li, Ronald Adolphus
Scientific Co-Founder, CEO & Director
(604) 398-3170
-

Costa, Kevin 
Chief Scientific Officer & Scientific Co-Founder
604-398-3170
-

Khine, Michelle 
Scientific Co-Founder & Member of Scientific Advisory Board
604-398-3170
-

Chan, Camie 
Interim CFO, COO, Corporate Secretary & Director
+1 604-398-3170
(604) 375-5578

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
